World Health Organization [homepage on the Internet].data.who.int, WHO Coronavirus (COVID-19) dashboard > Cases [Dashboard]. [updated 2024 May 5; cited 2024 May 23] Available from: https://data.who.int/dashboards/covid19/cases?n=c.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–93.

Article  CAS  PubMed  Google Scholar 

Cao B, Wang Y, Lu HZ, Huang CL, Yang YM, Shang LH, et al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N Engl J Med. 2024;390:230–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang FX, Xiao W, Tang YM, Cao ML, Shu D, Asakawa T, et al. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo- controlled, phase 1b trial. Lancet Reg Health West Pac 2023;38:100835.

Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, et al. Structure-based development and preclinical evaluation of the SARS-CoV-23C-like protease inhibitor simnotrelvir. Nat Commun. 2023;14:6463.

Yang XM, Yang Y, Yao BF, Ye PP, Xu Y, Peng SP, et al. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur J Pharm Sci. 2023;191:106598.

Ramamoorthy A, Bende G, Chow ECY, Dimova H, Hartman N, Jean D, et al. Human radiolabeled mass balance studies supporting the FDA approval of new drugs. Clin Transl Sci. 2022;15:2567–75.

Article  PubMed  PubMed Central  Google Scholar 

Pearson D, Garnier M, Luneau A, James AD, Walles M. 19)F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers. Xenobiotica. 2019;49:953–60.

Article  CAS  PubMed  Google Scholar 

Singh RSP, Walker GS, Kadar EP, Cox LM, Eng H, Sharma R, et al. Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: a novel approach for accelerating drug development. Clin Pharmacol Ther. 2022;112:1201–6.

Article  CAS  PubMed  Google Scholar 

James AD, Marvalin C, Luneau A, Meissner A, Camenisch G. Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017;45:900–7.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration: Bioanalytical Method Validation Guidance for Industry. 2018; Available from: https://www.fda.gov/media/70858/download.

U.S. Food and Drug Administration: Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies. 2022; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies.

Asakura M, Fukami T, Nakajima M, Fujii H, Atsuda K, Itoh T, et al. Hepatic dipeptidyl peptidase-4 controls pharmacokinetics of vildagliptin in vivo. Drug Metab Dispos. 2017;45:237–45.

Article  CAS  PubMed  Google Scholar 

Kong FD, Pang XY, Zhao JH, Deng P, Zheng MY, Zhong DF, et al. Hydrolytic metabolism of cyanopyrrolidine DPP-4 inhibitors mediated by dipeptidyl peptidases. Drug Metab Dispos. 2019;47:238–48.

Article  CAS  PubMed  Google Scholar 

Wang K, Zhang ZW, Hang J, Liu J, Guo FS, Ding Y, et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science. 2023;381:501.

Article  Google Scholar 

Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep. 2009;61:899–908.

Article  CAS  PubMed  Google Scholar 

Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther. 2022;112:101–11.